86 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28072531	120	Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.	Arena Pharmaceuticals
28523115	59	Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP	Novartis Institutes For Biomedical Research
28169162	86	Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.	Askat
28105284	55	Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.	Ono Pharmaceutical
26985320	89	Discovery of G Protein-Biased EP2 Receptor Agonists.	Ono Pharmaceutical
27133594	6	Piperidine derivatives as nonprostanoid IP receptor agonists 2.	Toray Industries
27107947	30	Optimization of amide-based EP3 receptor antagonists.	Pfizer
27020304	31	Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.	Eli Lilly
26996371	27	Piperidine derivatives as nonprostanoid IP receptor agonists.	Toray Industries
27055938	82	Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.	Ono Pharmaceutical
26764191	38	Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.	Eli Lilly
26725951	46	Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.	Ono Pharmaceutical
26091726	41	Discovery and characterization of a potent and selective EP4 receptor antagonist.	Eli Lilly
26101562	4	Prostaglandin EP3 Receptor Antagonists May Provide Novel Treatment for Diabetes.	Therachem Research Medilab (India)
26061158	136	A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.	Amgen
24279689	56	Prostanoid receptor EP2 as a therapeutic target.	Emory University
24021582	52	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.	Novartis Institutes For Biomedical Research
21676612	33	Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists.	Glaxosmithkline
21413808	170	Synopsis of some recent tactical application of bioisosteres in drug design.	Bristol-Myers Squibb Pharmaceutical Research and Development
24900547	23	Fluorescent Human EP3 Receptor Antagonists.	TBA
24900213	25	Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.	TBA
18359630	37	Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.	Merck Frosst Canada
18039575	35	Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist.	Emd-Serono Research Institute
18291643	76	Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.	Merck Frosst Centre For Therapeutic Research
17531488	44	Discovery of novel prostaglandin analogs of PGE2 as potent and selective EP2 and EP4 receptor agonists.	Emd-Serono Research Institute
16931013	138	Comparison between two classes of selective EP(3) antagonists and their biological activities.	Merck Frosst Centre For Therapeutic Research
15664806	104	Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists.	Merck Frosst Centre For Therapeutic Research
15914004	34	Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.	Fujisawa Pharmaceutical
12643927	164	Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.	Merck Frosst Centre For Therapeutic Research
21208803	81	The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.	Merck Frosst Centre For Therapeutic Research
21036609	38	Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.	Merck Frosst Centre For Therapeutic Research
20926294	65	3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.	Glaxosmithkline
20471829	43	Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.	Merck Frosst Canada
20218623	68	Emerging targets in osteoporosis disease modification.	Amgen
20303752	143	1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists.	Decode Chemistry
19836233	31	Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.	Decode Chemistry
20163116	116	The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.	Merck Frosst Centre For Therapeutic Research
19957930	126	Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that	Decode Chemistry
19592244	61	7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.	Novartis Institutes of Biomedical Research
19487124	39	Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.	Glaxosmithkline
19332369	43	Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.	Glaxosmithkline
19307115	89	Discovery of potent and selective DP1 receptor antagonists in the azaindole series.	Merck Frosst Centre For Therapeutic Research
19188065	116	3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.	Decode Chemistry
19121942	57	Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists.	Decode Chemistry
19036582	45	Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.	Glaxosmithkline
19022669	116	3,4-Disubstituted indole acylsulfonamides: a novel series of potent and selective human EP3 receptor antagonists.	Decode Chemistry
18701276	97	Highly functionalized 7-azaindoles as selective PPAR gamma modulators.	Merck Research Laboratories
17300164	62	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).	Merck Frosst Canada
16529930	96	Identification of an indole series of prostaglandin D2 receptor antagonists.	Merck Frosst Canada
16442794	95	Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats.	Pfizer
15935659	17	Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.	Fujisawa Pharmaceutical
15857112	55	Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.	Fujisawa Pharmaceutical
15566283	43	Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents.	Roche Palo Alto
15026044	90	Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization.	Roche Palo Alto
14552786	88	Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
12182865	88	Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
11708917	33	Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.	Procter & Gamble Pharmaceuticals
32201020	26	Novel pyridone EP	Inception Sciences Canada
11266183	32	Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.	Merck Frosst Canada
10915040	84	Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.	Procter & Gamble Pharmaceuticals
10715159	112	Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.	Procter and Gamble Pharmaceuticals
10509919	103	New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
30964292	42	Difluoromethylene at the ?-Lactam ?-Position Improves 11-Deoxy-8-aza-PGE	Cayman Chemical
31855426	98	Discovery and Characterization of 1	East China Normal University
29995405	56	Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.	Ube Industries
26608552	46	Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists.	Eli Lilly
24094816	28	Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.	Asahi Kasei Pharma
21514150	26	Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.	Glaxosmithkline
29636218	43	Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP	Glaxosmithkline
29203142	40	Synthesis and evaluation of a potent, well-balanced EP	Ono Pharmaceutical
29934246	12	Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EP	Asahi Kasei Pharma
16852171	6	Complexation of adamantyl compounds by beta-cyclodextrin and monoaminoderivatives.	Universidade De Santiago De Compostela